News Release

2019

September 6, 2019

National Center of Neurology and Psychiatry and EA Pharma Co., Ltd. Sign a Global License Agreement for OCH-NCNP1

August 29, 2019

EA Pharma Invests in a New Venture Capital Fund

February 19, 2019

EA Pharma Signs A License Agreement with Dr. Falk Pharma GmbH for A Novel Liver Disease Treatment “nor-Ursodeoxycholic Acid” for Japan Market

2018

December 19, 2018

EA Pharma Signs License Agreement with Synmosa for Chronic Constipation Treatment AJG533

November 29, 2018

MOVICOL® Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

November 8, 2018

Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn’s Disease Concluded, Research Activities Commence

September 21, 2018

Marketing and Manufacturing Approval of Chronic Constipation Treatment “MOVICOL®” Obtained in Japan

July 9, 2018

Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment “GOOFICE® 5mg Tablet” Published in The Lancet Gastroenterology & Hepatology

June 12, 2018

EA Pharma Signed a License Agreement with TASLY PHARMACEUTICAL GROUP for Secondary Hyperparathyroidism Treatment AJT240

June 11, 2018

AbbVie and Eisai Announce the Launch of HUMIRA® Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA®

May 28, 2018

PIII Clinical Study Data on Chronic Constipation Treatment“GOOFICE® 5mg Tablet” Will Be Presented at DDW2018

May 25, 2018

POTENT NEW MECHANISM OF ACTION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE REVEALED

April 19, 2018

World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan

March 30, 2018

EA Pharma Obtained “Marketing License for Medical Devices”

March 22, 2018

EA Pharma Signs A License Agreement with Cosmo Technologies Ltd.for Colonoscopy-relating Products “Methylene Blue MMX” and “Eleview”for Japan and South Korea Markets

March 9, 2018

“LIVACT® Granules”－A Branched-chain Amino Acid Formula –Launches in Thailand

January 19, 2018

New drug approval of bile acid transporter inhibitor “GOOFICE® 5mgTablet” for chronic constipation was obtained in Japan.

2017

December 6, 2017

Ulcerative Colitis Treatment“RECTABUL® 2 mg Rectal Foam 14 Doses” Launches in Japan

November 27, 2017

Application for Marketing and Manufacturing Approval of Chronic ConstipationTreatment AJG555 Was Filed in Japan

October 31, 2017

EA Pharma Signed a License Agreement with JW Pharmaceutical for Secondary Hyperparathyroidism Treatment AJT240